Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Specialty pharmaceutical firm Prometheus Laboratories has begun exclusive US marketing, sales and distribution of AstraZeneca's Entocort EC in Crohn's disease, an inflammatory bowel disease.
Subscribe to our email newsletter
AstraZeneca launched Entocort EC (budesonide) capsules in November 2001. In November 2004, Prometheus entered into an agreement with AstraZeneca for the marketing, sales and distribution of Entocort EC, beginning in January 2005.
Entocort EC is a first-line therapy and the only pharmacological product indicated for the treatment of mild to moderate active Crohn’s disease involving the ileum and/or the ascending colon, the sites of disease for approximately 70% of patients.
Entocort EC is a non-systemic glucocorticosteriod, which means that it works locally or in one area of the body.
“Entocort EC is a very important product for physicians and patients, as it is the only FDA-approved product for the majority of Crohn’s patients with mild to moderate active disease,” noted Clyde Shores, Prometheus’ vice president of marketing. “The addition of Entocort EC to our portfolio is also an important step in Prometheus’ strategy of expanding our commercial franchise with clinically meaningful and proprietary products.”